某院2014年度嗜麦芽窄食假单胞菌的耐药性及分布

目的探讨院内分离的嗜麦芽窄食假单胞菌的耐药性及分布，为临床经验用药提供理论依据。 方法应用WHONET 5.6软件对2014年1月至12月本院临床分离的163株嗜麦芽窄食假单胞菌的耐药性及分布进行分析。 结果163株嗜麦芽窄食假单胞菌对头孢他啶、替卡西林/克拉维酸、左旋氧氟沙星和复方新诺明的耐药率依次为65.0%（106/163）、39.9%（65/163）、3.7%（6/163）和1.2%（2/163）。其中78.5%（128/163）的标本来源于痰液，16.0%（26/163）的标本来源于血液；41.7%（68/163）的标本来自ICU重症监护病房；21.5%（35/163）的标本来自儿内科病房。 结论嗜麦芽窄食假单胞菌主要引起呼吸道感染，其次是血流感染。临床治疗嗜麦芽窄食假单胞菌引起的感染，经验用药可选用左旋氧氟沙星或复方新诺明。

Drug resistance and clinical distribution of Stenotrophomonas maltophilia in a hospital in 2014

ObjectiveTo investigate the drug resistance and clinical distribution of Stenotrophomonas maltophilia collected from our hospital, and to guide rational clinical application of antibacterial. MethodsTotal of 163 stains of Stenotrophomonas maltophilia were collected from January 2014 to December 2014, the drug resistance rates and clinical distribution were analyzed by WHONET 5.6 software, retrospectively. ResultsThe drug resistance rates of 163 stains of Stenotrophomonas maltophilia to ceftazidime, ticarcillin/clavulanic acid, levofloxacin and cotrimoxazole were 65.0% (106/163), 39.9% (65/163), 3.7% (6/163) and 1.2% (2/163). Among the 163 strains, 78.5% (128/163) were obtained from sputum, 16.0% (26/163) were obtained from blood; 41.7% (68/163) were collected from intensive care unit, and 21.5% (35/163) were collected from pediatric ward. ConclusionsStenotrophomonas maltophilia strains collected from our hospital mainly caused respiratory tract infection, followed by bloodstream infection. Infection caused by Stenotrophomonas maltophilia could be treated with levofloxacin or cotrimoxazole.